Janus Henderson Amends Altimmune Stake Filing
Ticker: JHG · Form: SC 13G/A · Filed: Feb 12, 2024 · CIK: 1274173
| Field | Detail |
|---|---|
| Company | Janus Henderson Group PLC (JHG) |
| Form Type | SC 13G/A |
| Filed Date | Feb 12, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**Janus Henderson still owns Altimmune stock, signaling continued institutional interest.**
AI Summary
Janus Henderson Group plc, a major investment advisor, filed an amended SC 13G/A on February 12, 2024, indicating its ownership of Altimmune, Inc. Common Stock as of December 31, 2023. This filing, an amendment to a previous disclosure, signals that Janus Henderson continues to hold a significant stake in Altimmune, a pharmaceutical preparations company. For investors, this matters because it shows a large institutional investor maintains confidence in Altimmune, potentially signaling stability or future growth prospects for the stock.
Why It Matters
This filing confirms a major institutional investor, Janus Henderson Group plc, continues to hold a significant position in Altimmune, Inc., which can be a positive signal for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate negative or highly volatile events.
Analyst Insight
Investors should note that a major institutional player, Janus Henderson, continues to hold Altimmune stock. While this doesn't guarantee future performance, it suggests ongoing institutional confidence. It would be prudent to monitor future filings for changes in their ownership percentage and consider this alongside Altimmune's operational performance.
Key Players & Entities
- Janus Henderson Group plc (company) — the reporting person and investment advisor
- Altimmune, Inc. (company) — the subject company whose common stock is owned
- December 31, 2023 (date) — the date of the event requiring the filing
- February 12, 2024 (date) — the filing date of the SC 13G/A amendment
Forward-Looking Statements
- Janus Henderson Group plc will maintain its significant stake in Altimmune, Inc. throughout 2024. (Janus Henderson Group plc) — medium confidence, target: 2024-12-31
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing under the Securities Exchange Act of 1934, as indicated by 'FORM TYPE: SC 13G/A' and 'Amendment No.: 1*'.
Who is the reporting person in this filing?
The reporting person is Janus Henderson Group plc, as stated under '1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Henderson Group plc'.
What company's securities are being reported on?
The securities being reported on are those of Altimmune, Inc., specifically 'Common Stock', as listed under 'Name of Issuer: ALTIMMUNE, INC.' and 'Title of Class of Securities: Common Stock'.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified by 'Date of Event Which Requires Filing of this Statement: 12/31/2023'.
Under which rule was this Schedule 13G/A filed?
This Schedule 13G/A was filed under Rule 13d-1(b), indicated by the 'X' next to '[X] Rule 13d-1(b)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 12, 2024 regarding JANUS HENDERSON GROUP PLC (JHG).